Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Marginal Zone Lymphoma

Marginal Zone Lymphoma

Part of Cancer

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Marginal Zone Lymphoma

88 trials tracked for Marginal Zone Lymphoma: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 226 citations.

88Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 73 Phase 1 6 Other / NA 7
  1. Phase 3 Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma Completed · 226 cited
  2. Phase 3 A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Completed · 8 cited
  3. Phase 2 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Completed
  4. Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Completed
  5. Phase 2 A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) Completed
  6. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
Show 44 more trials
  1. Phase 2 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Completed
  2. Phase 2 Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma Completed
  3. Phase 2 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Completed
  4. Phase 2 Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma Completed
  5. Phase 2 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma Completed
  6. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  7. Phase 2 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma Completed
  8. Phase 2 Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma Completed
  9. Phase 2 Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma Completed
  10. Phase 2 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed
  11. Phase 2 A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Completed
  12. Phase 2 Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma Completed
  13. Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed
  14. Phase 2 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed
  15. Phase 2 Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Completed
  16. Phase 2 Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas Completed
  17. Phase 2 Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Completed
  18. Phase 2 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Completed
  19. Phase 2 Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma Completed
  20. Phase 2 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed
  21. Phase 2 High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Completed
  22. Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Completed
  23. Phase 2 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed
  24. Phase 2 A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Completed
  25. Phase 2 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma Completed
  26. Phase 2 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Completed
  27. Phase 2 Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma Completed
  28. Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed
  29. Phase 2 Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Completed
  30. Phase 2 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed
  31. Phase 2 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma Completed
  32. Phase 2 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed
  33. Phase 2 Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Completed
  34. Phase 2 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  35. Phase 2 Imexon for Relapsed Follicular and Aggressive Lymphomas Completed
  36. Phase 2 Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue Completed
  37. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Completed
  38. Phase 2 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed
  39. Phase 2 Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) Completed
  40. Phase 2 Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma Completed
  41. Phase 2 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Completed
  42. Phase 2 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Completed
  43. Phase 2 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed
  44. Phase 2 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Completed

Showing the 50 most-cited and recently-updated of 88 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Marginal Zone Lymphoma: what the trials found

Lenalidomide has demonstrated significant activity in patients with Marginal Zone Lymphoma. Clinical data show progression-free survival (PFS) rates at 18 weeks ranging from 85.7% to 100% and a duration of response rate at 2 years between 66.7% and 100% 4. Additional trials confirm the use of lenalidomide in this patient population 11.

Fludarabine is established as an intervention for Marginal Zone Lymphoma [3, 10]. Chlorambucil has shown high response rates, with complete and partial remission rates between 78.3% and 94.7%, and a five-year continuous remission rate of 66% to 79% 6.

Ibrutinib is established for use in this condition across multiple trials [16, 17]. Rituximab has been evaluated, though evidence regarding its impact on event-free survival did not reach statistical significance (p=0.26) 7.

Recent results — preliminary, needs further review

  • Mosunetuzumab is currently under investigation in a Phase 2 trial 1.
  • Bendamustine plus rituximab is being evaluated in a Phase 2 study 2.
  • BGB-10188 is undergoing evaluation in a Phase 2 trial 5.
  • Axicabtagene ciloleucel showed an objective response rate (ORR) of up to 92% and a complete response (CR) rate of up to 78% in a Phase 2 study; among patients with 3 or more prior lines of therapy, the ORR was 91% and 75% 8.
  • Nivolumab is being evaluated in a Phase 2 trial 9.

For the clinician treating this condition

  • Lenalidomide shows robust outcomes with high progression-free survival rates at both 18 weeks and 2 years [4, 11].
  • Chlorambucil demonstrates high remission rates with a majority of patients remaining in continuous remission at five years 6.
  • Ibrutinib is an established option for treatment [16, 17].
  • Axicabtagene ciloleucel shows high objective response rates even in heavily pre-treated patients 8.

AI synthesis of 9 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
Oncology FDA Approval
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
FDA May 2, 2026
Pirtobrutinib shows activity in relapsed and refractory marginal zone lymphoma patients in a Phase 1/2 trial
Oncology Phase I
Pirtobrutinib shows activity in relapsed and refractory marginal zone lymphoma patients in a Phase 1/2 trial Early trial shows pirtobrutinib helped some patients with relapsed marginal zone lymphoma
This Phase 1/2 trial evaluated pirtobrutinib in 36 patients with relapsed and refractory marginal zone lymphoma.
A new drug helped more than half of patients with relapsed lymphoma shrink their tumors, offering hope for those who have run out of other t…
Apr 16, 2026

Research across Cancer

Related studies from across the Cancer family.

EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA
Radiology & Imaging Meta-analysis
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA Core Biopsy Shows Higher Yield for Lymphoma and Sarcoidosis
This meta-analysis of 1434 patients with mediastinal disorders found that EBUS-TBNB provides a significantly higher diagnostic yield for lym…
A core biopsy technique may provide more accurate results than standard needle aspiration for certain conditions like lymphoma and sarcoidos…
Jun 13, 2026
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
Allergy & Immunology Sys. Review
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Frontiers Jun 11, 2026
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Hematology Sys. Review
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Frontiers May 23, 2026
Systematic review of preclinical CBD effects in canine cancers
Cardiology Meta-analysis
Systematic review of preclinical CBD effects in canine cancers Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
Frontiers May 22, 2026
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Infectious Disease Meta-analysis
Meta-analysis of double-expressor lymphoma prognoses and novel therapies Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Frontiers May 22, 2026
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
Oncology RCT
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
JAMA May 19, 2026
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma
Allergy & Immunology Sys. Review
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma Venetoclax combo shows promise for relapsed Hodgkin lymphoma
A 26-year-old with relapsed/refractory classical Hodgkin lymphoma achieved complete metabolic remission after 6 cycles of venetoclax, chidam…
A 26-year-old man with relapsed Hodgkin lymphoma achieved complete remission after a novel three-drug regimen, with no significant side effe…
Frontiers May 15, 2026
Case report and literature review highlights skin lesions as early AITL signs before lymphadenopathy
Oncology Sys. Review
Case report and literature review highlights skin lesions as early AITL signs before lymphadenopathy When a Skin Rash Signals a Hidden Blood Cancer
This case report and literature review examines cutaneous manifestations in a 63-year-old male with Angioimmunoblastic T-cell lymphoma treat…
A rare lymphoma can hide behind common-looking skin rashes and ulcers, causing dangerous delays in diagnosis that may last months.
Frontiers May 14, 2026
Literature review on primary CNS MALT lymphoma treatment and diagnosis
Oncology Sys. Review
Literature review on primary CNS MALT lymphoma treatment and diagnosis A Rare Brain Tumor in the Ventricles Was Found and Treated
This literature review and case report describes a 62-year-old man with primary central nervous system mucosa-associated lymphoid tissue lym…
A 62-year-old man had a rare brain tumor inside a fluid-filled ventricle, and a new treatment plan kept it from coming back.
Frontiers May 11, 2026
Narrative review of treatment strategies for primary central nervous system lymphoma
Dermatology Sys. Review
Narrative review of treatment strategies for primary central nervous system lymphoma A Smarter Way to Treat a Rare Brain Lymphoma Is Emerging
This narrative review covers treatment strategies for primary central nervous system lymphoma, including HD-MTX-based regimens, HDC-ASCT, an…
A rare lymphoma hiding in the brain now has sharper risk tools and smarter drug combos that could mean fewer relapses and less toxic treatme…
Frontiers May 8, 2026
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
Oncology Meta-analysis
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma New cancer therapies double response rates for tough lymphoma
This systematic review and meta-analysis of phase 1-2 trials evaluated experimental agents alone or combined with CD20-antibodies in adults …
Patients with aggressive lymphoma once had few options after standard treatments failed, but new therapies are changing that outlook in ways…
May 3, 2026
Systematic review and meta-analysis of interim FDG PET in large B-cell lymphoma patients
Hematology Meta-analysis
Systematic review and meta-analysis of interim FDG PET in large B-cell lymphoma patients Early PET scans help doctors predict how well large B-cell lymphoma treatments will work for patients
This systematic review and meta-analysis evaluated the utility of interim FDG PET (iPET) in 44 eligible studies involving large B-cell lymph…
A review of many studies shows that early PET scans can tell doctors if cancer treatment is working. This helps them decide the best next st…
May 2, 2026